Korea Asset Investment Securities Co., Ltd. (KOSDAQ:190650)
6,840.00
-350.00 (-4.87%)
At close: Jun 8, 2026
KOSDAQ:190650 Revenue
Korea Asset Investment Securities had revenue of 58.88B KRW in the quarter ending December 31, 2025, a decrease of -22.41%. This brings the company's revenue in the last twelve months to 239.47B, down -3.46% year-over-year. In the fiscal year ending March 31, 2025, Korea Asset Investment Securities had annual revenue of 248.07B with 22.70% growth.
Revenue (ttm)
239.47B
Revenue Growth
-3.46%
P/S Ratio
0.18
Revenue / Employee
n/a
Employees
n/a
Market Cap
43.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 248.07B | 45.90B | 22.70% |
| Mar 31, 2024 | 202.17B | -8.75B | -4.15% |
| Mar 31, 2023 | 210.92B | 3.38B | 1.63% |
| Mar 31, 2022 | 207.54B | 53.09B | 34.37% |
| Mar 31, 2021 | 154.46B | -56.58B | -26.81% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sewon Co.,Ltd | 242.11B |
| RP Bio | 137.35B |
| Hyper Corporation | 80.77B |
| Seoulin Bioscience | 78.58B |
| ISAAC Engineering Co.,Ltd | 77.61B |
| Green Lifescience | 51.02B |
| J2KBIO | 36.82B |
| Egis Co.,Ltd | 21.41B |